Compare Adaptive Biotechnologies Corp (ADPT) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Genuine Parts Company — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Genuine Parts Company trades at $124.37 (market cap $17.71B). The key difference: Genuine Parts Company is far larger — about 5.3× Adaptive Biotechnologies Corp's market cap, and Genuine Parts Company pays a 3.3% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GPC | |
|---|---|---|
Market Cap | $3.33B | $17.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $149.26 |
52-Week Low | $10.24 | $92.47 |
Enterprise Value | $3.19B | $23.92B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GPC trades at $128.67, down 2.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results due July 21, 2026. Financials show revenue growth to $24.3B in 2025 but a sharp decline in net income margin to 0.24%, while the P/E ratio of 292.41 reflects high valuation relative to earnings. A dividend of $1.06 per share is scheduled for payment on July 2, 2026.
The outlook is cautious due to weak profitability and high P/E, but analyst consensus is a Buy with a $133 price target, suggesting modest upside. Risks include earnings volatility and competitive pressures in the automotive parts sector. The stock's near-term direction hinges on Q2 2026 earnings, with support at $126 and resistance at $131.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
